We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




Events

09 Apr 2024 - 12 Apr 2024
15 Apr 2024 - 17 Apr 2024
23 Apr 2024 - 26 Apr 2024

Blood Test for Gut Bacteria Predicts Cardiovascular Events

By LabMedica International staff writers
Posted on 02 Feb 2017
Print article
Image: The Nexera ultra high performance liquid chromatograph (UHPLC) system (Photo courtesy of Shimadzu).
Image: The Nexera ultra high performance liquid chromatograph (UHPLC) system (Photo courtesy of Shimadzu).
The bacteria that inhabit the gut digest food and produce metabolites that can have a marked effect on the heart and blood vessels. A molecule called trimethylamine N-oxide (TMAO) could predict this risk not only in the short-term but also the risk of death in the longer term.

TMAO is produced by the gut bacteria from components of red meat, eggs and dairy products and in the blood could give a quick and reliable way of assessing the risk of death and other major heart problems in patients who arrive in hospital emergency departments with chest pains.

A large team of scientists led by those at the University Hospital Zurich examined TMAO levels in the blood of 530 patients, aged over 18, arriving in the emergency department of the Cleveland Clinic with chest pains, and 1,683 patients who had coronary angiography within five days after being admitted to one of four university hospitals in Switzerland (Zurich, Bern, Lausanne and Geneva) with chest pains. The patients were followed up for several years to monitor for outcomes such as death from any cause, death from heart and blood vessel problems, heart attack, stroke or revascularisation.

For the Cleveland cohort, routine laboratory testing was performed, including the Roche cTnT (4th generation) assay. Trimethylamine N-oxide levels in plasma were determined using stable isotope dilution high-performance liquid chromatography with on line electrospray ionization tandem mass spectrometry (LC/MS/MS) using d9-(trimethyl)-labelled internal standard on a Shimadzu 8050 triple quadrupole mass spectrometer interfaced to a Nexera Ultra High Performance Liquid Chromatograph (UHPLC) system.

The team found that an elevated plasma TMAO level at presentation was independently associated with risk of major adverse cardiac events (MACE, including myocardial infarction, stroke, need for revascularization, or death) over the ensuing 30-day and 6-month intervals. TMAO levels were also a significant predictor of the long term (7-year) mortality. Interestingly, TMAO level at initial presentation predicted risk of incident MACE over the near-term (30 days and six months) even among subjects who were initially negative for troponin T (less than 0.1 ng/mL).

In both groups of patients, those with TMAO levels above 2.5 μm seemed to be at higher risk. However, after adjusting for other risk factors and medical conditions, the increased risk was seen to start at 4.28 μm in the US patients and 4.85 μm in the Swiss. Testing for TMAO is quick and easy to perform in the laboratory and is inexpensive as in the USA hospitals can carry it out for around USD 50-55. The study was published on January 11, 2017, in the European Heart Journal.

Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
One Step HbA1c Measuring System
GREENCARE A1c
POCT Fluorescent Immunoassay Analyzer
FIA Go
New
Gold Member
Plasma Control
Plasma Control Level 1

Print article

Channels

Molecular Diagnostics

view channel
Image: MOF materials efficiently enrich cfDNA and cfRNA in blood through simple operational process (Photo courtesy of Science China Press)

Blood Circulating Nucleic Acid Enrichment Technique Enables Non-Invasive Liver Cancer Diagnosis

The ability to diagnose diseases early can significantly enhance the effectiveness of clinical treatments and improve survival rates. One promising approach for non-invasive early diagnosis is the use... Read more

Hematology

view channel
Image: The low-cost portable device rapidly identifies chemotherapy patients at risk of sepsis (Photo courtesy of 52North Health)

POC Finger-Prick Blood Test Determines Risk of Neutropenic Sepsis in Patients Undergoing Chemotherapy

Neutropenia, a decrease in neutrophils (a type of white blood cell crucial for fighting infections), is a frequent side effect of certain cancer treatments. This condition elevates the risk of infections,... Read more

Pathology

view channel
Image: The OvaCis Rapid Test discriminates benign from malignant epithelial ovarian cysts (Photo courtesy of INEX)

Intra-Operative POC Device Distinguishes Between Benign and Malignant Ovarian Cysts within 15 Minutes

Ovarian cysts represent a significant health issue for women globally, with up to 10% experiencing this condition at some point in their lives. These cysts form when fluid collects within a thin membrane... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.